Introduction

Few areas of research have developed as quickly as cancer cell therapy. Over the past decade, conceptual and technical advances have transformed what can be measured and engineered1–4, and have brought long-standing questions within reach of experiment5,6.

Yet the field continues to be shaped by the immunosuppressive microenvironment of solid tumours7. In this article, we survey recent progress, highlight emerging consensus and disagreement, and identify the developments most likely to move the field forward.

Foundations

Early work established the core concepts and the first quantitative models8–10. These frameworks remain useful but rest on simplifying assumptions whose limits are increasingly apparent11.

A unifying theme is that progress has come from combining new measurements with models that make falsifiable predictions.

Recent advances

Three developments stand out. First, new experimental platforms allow systematic, high-throughput measurements12–14. Second, computational methods now enable predictions that can be tested directly15,16. Third, large collaborative datasets have made it possible to compare results across laboratories and systems17.

Approach Strengths Limitations
Controlled experiments Causal inference, precision Limited scale and realism
Large-scale observation Generality, statistical power Confounding factors
Computational models Mechanistic insight, prediction Dependence on assumptions

Open questions

Important questions remain unresolved, including how findings generalize across scales and contexts18, and how best to translate insight into application19,20.

Outlook

We anticipate that the next decade will see cancer cell therapy move from proof-of-principle demonstrations to robust, predictive science. Achieving this will require shared standards, open data and sustained support for interdisciplinary teams.